Complement 3 glomerulopathy

MONDO:0018013

A rare primary membranoproliferative glomerulonephritis characterized by complement dysregulation occurring in the fluid phase and in the glomerular microenvironment, which results in prominent complement C3 deposition in kidney biopsy samples.

Also known as: C3 glomerulopathy, C3G, non-Ig-mediated MPGN, non-Ig-mediated membranoproliferative glomerulonephritis, non-immunoglobulin-mediated MPGN, non-immunoglobulin-mediated membranoproliferative glomerulonephritis

27 clinical trials for this condition and its sub-types, 23 tagged with Complement 3 glomerulopathy itself.

Follow this condition to get notified about new trials

Where it sits in the disease tree

Browse by category →

Part of

↑ Primary membranoproliferative glomerulonephritis (26)

Sub-types of Complement 3 glomerulopathy

C3 glomerulonephritis 7 trials
Dense deposit disease 5 trials
Complement factor H deficiency 0 trials
1 sub-type
- Immunodeficiency with factor H anomaly 0 trials

Including sub-types (27) Tagged with Complement 3 glomerulopathy (23)

Trials to join now! 11 Not yet recruiting 7 Not yet finished but already full! 5 Completed 3 Terminated 1

New drug OMS721 tested for rare kidney conditions

Disease control Stopped early

This study tested a drug called OMS721 in 31 people with certain kidney diseases, including IgA nephropathy and lupus nephritis. The main goal was to check if the drug is safe and if it reduces protein in the urine, a sign of kidney damage. The study was stopped early, so results…

Phase 2 • Sponsor: Omeros Corporation • Aim: Disease control

Last updated Jun 27, 2026 12:02 UTC

Complement 3 glomerulopathy

Where it sits in the disease tree

New drug OMS721 tested for rare kidney conditions